Blood And Blood Components Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Blood And Blood Components Market Trends and Insights

Rising Surgical Volumes in Complex Specialties

Outpatient procedures in the United States are expected to climb 21% during 2025 to 2035, illustrating the shift toward ambulatory care. Complex oncologic resections and robotic-assisted orthopedic cases still mandate cross-matched red cells and platelets on standby, sustaining hospital inventories. Satellite blood depots are proliferating near large ambulatory surgical centers, yet decentralized stock elevates cold-chain overheads and demands real-time visibility. FDA Current Good Tissue Practice and AABB standards oblige these centers to document transfusion protocols, adding compliance costs that only large systems can easily absorb.

Oncology-Induced Anemia and Thrombocytopenia Support

CAR-T and high-dose chemotherapy produce severe cytopenias in 10-25% of treatment cycles, triggering prophylactic platelet transfusions below 10,000/μL as guided by ASCO and ASH^{[2]National Cancer Institute, “Bleeding & Bruising,” cancer.gov}. Hospitals are adopting pathogen-reduction platforms such as INTERCEPT, cleared by the FDA in 2025, to extend shelf life and curb bacterial contamination. As survival improves, each patient requires more transfusions over a longer horizon, reinforcing steady growth for the blood and blood components market.

Trauma and Road-Injury Burden Elevating Emergency Transfusions

Trauma-induced coagulopathy affects up to 35% of severely injured patients, necessitating 1:1:1 resuscitation ratios endorsed by the WHO. The FDA’s 2023 guidance on cold-stored platelets enables prehospital deployment in rural ambulances, military field hospitals, and disaster caches^{[3]U.S. Food and Drug Administration, “Guidance for Cold-Stored Platelets,” fda.gov}. The CHIPS trial, now enrolling, may extend permissible storage to 21 days, a potential game-changer for low-resource trauma networks.

Aging Populations Increasing Perioperative Transfusion Intensity

Adults ≥ 65 years old present higher baseline anemia and polypharmacy, which elevate transfusion probability during orthopedic and cardiac operations. Japan, where citizens ≥ 65 represent 29% of the population, has intensified donor-recruitment campaigns to offset waning participation among younger cohorts. Adults ≥ 65 years old present higher baseline anemia and polypharmacy, which elevate transfusion probability during orthopedic and cardiac operations. Japan, where citizens ≥ 65 represent 29% of the population, has intensified donor-recruitment campaigns to offset waning participation among younger cohorts.

Patient Blood Management Reducing Allogeneic Transfusions

PBM bundles preoperative anemia correction, intraoperative cell salvage, and restrictive thresholds have cut red-cell use by up to 60% and reduced mortality odds to 0.33 in German multicenter studies. Joint Commission standards now oblige hospitals to audit transfusion appropriateness, compressing demand even as surgical complexity climbs.

Shrinking Donor Pools and Seasonal Shortages

The American Red Cross reported a 40% decline in teen and young-adult donors over two decades. Japan mirrors the trend as its population ages; older donors now outnumber younger contributors. Mobile drives and social-media campaigns restored only single-digit growth in first-time donors, leaving inventory gaps during holidays that inflate procurement costs.

Segment Analysis

By Component: Platelets Gain Share Despite RBC Dominance

Red blood cells generated 65.18% of 2025 revenue, yet platelets are on track for a 6.50% CAGR to 2031 as CAR-T and intensified chemotherapy expand thrombocytopenia cases. Plasma and cryoprecipitate continue to support coagulation-factor replacement in massive transfusion protocols, but pathogen-reduction systems are shifting the mix toward higher-margin, longer-shelf-life platelet products. INTERCEPT’s 2025 FDA authorization is emblematic of technology’s role in this shift.

Whole-blood-derived platelets remain critical across regions with limited apheresis capacity, yet stringent bacterial-contamination rules now add USD 50-100 to per-unit costs, nudging hospitals toward safer, pretreated supplies. Plasma fractionation investments, EUR 160 million by Grifols in Barcelona, underline a tilt toward derivatives with stronger margins.

By Collection Method: Apheresis Automation Drives Yield Gains

Whole-blood collections captured 72.18% of 2025 revenue thanks to entrenched mobile drives, but apheresis is heading for a 6.92% CAGR through 2031. Fresenius Kabi’s Aurora Xi software, cleared in 2025, raised plasma yield by 88 mL per donation, illustrating the incremental productivity that sustains apheresis growth.

Mobile collection remains indispensable for rural outreach, yet suppliers are exiting low-margin businesses. Haemonetics sold its whole-blood assets to GVS for USD 67.1 million in 2025 to focus on plasma and platelet automation. China’s updated 2024 guidelines similarly prioritize automated, pathogen-reduced collections, securing momentum for apheresis in Asia-Pacific.

By Application: Hemato-Oncology Support Outpaces Traditional Indications

Anemia and chronic disease management held 43.18% revenue in 2025, but cancer treatment and hemato-oncology support should clock a 6.76% CAGR through 2031 as durable CAR-T responses lengthen transfusion dependence. Massive transfusion in trauma continues to rely on 1:1:1 protocols, while the adoption of viscoelastic testing in obstetric hemorrhage sustains cryoprecipitate use.

Geographic concentration varies; trauma protocols dominate in the Middle East & Africa, whereas hemato-oncology peaks in North America, Europe, and urban China. WHO guidance on postpartum hemorrhage, including tranexamic acid and cryoprecipitate, widens demand in lower-income regions.

By End User: Ambulatory Centers Capture Outpatient Shift

Hospitals retained 68.19% revenue in 2025 because only they maintain 24/7 blood banks capable of emergency release. Ambulatory surgical centers, however, are growing at 6.55% a year as minimally invasive procedures accelerate. This decentralization forces blood centers to set up satellite depots, inflating logistics costs and requiring digital inventory platforms compliant with AABB traceability rules.

Standalone blood centers such as Vitalant consolidated operations in 2024-2025 to cushion PBM-driven volume drops. ASC operators now invest in transfusion-preparedness training and cross-matching protocols, acknowledging the limits of “low-risk” elective surgery models.

Geography Analysis

North America contributed 36.19% of global revenue in 2025, maintaining the largest blood and blood components market share. The U.S. FDA guidance in 2023 that permits 14-day cold storage of platelets lets trauma centers place inventory closer to remote highways and emergency medical services. This regulatory flexibility reduces wastage from expired units and supports steady growth even as Patient Blood Management programs restrain red-cell demand in urban hospitals. Persistent donor shortages remain a structural challenge, highlighted by the American Red Cross declaration of a national shortage in January 2024.

Asia-Pacific is forecast to log a 6.81% CAGR through 2031, the fastest among all regions within the blood and blood components market. China’s hospital capacity boost, coupled with a USD 2.4 billion CAR-T segment that is expanding at 28.9% annually, lifts platelet demand and accelerates adoption of apheresis automation. Japan’s aging population, where citizens over 65 already exceed 29%, forces the Japanese Red Cross to run targeted youth campaigns and pilot extended eligibility criteria to stabilize donations. Regional regulators are still evaluating pathogen-reduction and genotyping protocols pioneered in the West, creating a patchwork of standards that suppliers must navigate to unlock the full Asia-Pacific opportunity

Europe shows steady but slower expansion as national blood services roll out large-scale genotyping that cut alloimmunization in sickle-cell cohorts by up to 90%. Even so, summer vacations and year-end holidays still depress donor turnout by 15-20%, prompting elective-surgery cancellations and inter-country unit transfers within the European Union. Middle East and Africa as well as South America face higher trauma burdens and fragmented collection networks, driving hospitals to prioritize O-negative stocks and adopt cold-stored platelet protocols endorsed by the WHO.